Kim Hyun Kyung, Lee Kyoung Rhan, Yang Jeon Ho, Yoo Sung Jae, Lee Sang Won, Jang Hyun-Jung, Park Sang Jae, Moon Young-Soo, Park Joong-Won, Kim Chang-Min
Research Institute and Hospital, National Cancer Center, 809, Madu 1, Ilsan, Goyang, Gyeonggi, 411-764, South Korea.
Thromb Res. 2003 Jan 25;109(2-3):125-9. doi: 10.1016/s0049-3848(03)00183-x.
Fibrin formation and removal occurs continuously during the development of malignancy. Moreover, plasma D-dimer is indicative of ongoing fibrinolysis, and soluble fibrin polymer (Thrombus precursor protein, TpP) represents thrombogenic activity. We evaluated the relationship between the levels of plasma D-dimer and TpP and tumor thrombosis in patients with hepatocellular carcinoma (HCC), and examined these markers as possible predictors of tumor thrombus in the portal or the hepatic vein.
Plasma levels of D-dimer and TpP were measured in 66 HCC patients (38 without tumor thrombosis, 28 with tumor thrombosis) and 29 healthy controls, by enzyme immunoassay using an Asserachrom D-Di kit (Diagnostica Stago, France) and a TpP kit (American Biogenetic Sciences, USA).
The plasma levels of D-dimer and TpP in HCC patients were found to be significantly higher than those in healthy controls, and these values were also significantly higher in patients with tumor thrombosis than those without tumor thrombosis. Positive D-dimer (>367 ng/ml) correlated weakly with the presence of tumor thrombosis, whereas positive TpP (>5.4 microg/ml) correlated strongly with the presence of tumor thrombosis. By multivariant logistic analysis, positive TpP level was found to be a significant predictor of the presence of tumor thrombosis. In contrast, positive D-dimer level was not found to be a significant predictor for predicting tumor thrombosis.
Increased D-dimer and TpP levels in HCC may suggest that fibrinolysis and coagulation occur continuously during tumor progression. This study shows that a positive TpP level is a predictor of tumor thrombosis in HCC, which suggests that TpP may be useful for identifying tumor thrombus in the portal and hepatic veins.
在恶性肿瘤发展过程中,纤维蛋白的形成与清除持续发生。此外,血浆D-二聚体指示正在进行的纤维蛋白溶解,而可溶性纤维蛋白聚合物(血栓前体蛋白,TpP)代表血栓形成活性。我们评估了肝细胞癌(HCC)患者血浆D-二聚体和TpP水平与肿瘤血栓形成之间的关系,并将这些标志物作为门静脉或肝静脉肿瘤血栓的可能预测指标进行检测。
采用Asserachrom D-Di试剂盒(法国Diagnostica Stago公司)和TpP试剂盒(美国American Biogenetic Sciences公司),通过酶免疫测定法,检测了66例HCC患者(38例无肿瘤血栓,28例有肿瘤血栓)和29例健康对照者的血浆D-二聚体和TpP水平。
发现HCC患者的血浆D-二聚体和TpP水平显著高于健康对照者,且有肿瘤血栓患者的这些值也显著高于无肿瘤血栓患者。D-二聚体阳性(>367 ng/ml)与肿瘤血栓形成的相关性较弱,而TpP阳性(>5.4 μg/ml)与肿瘤血栓形成的相关性较强。通过多变量逻辑分析,发现TpP阳性水平是肿瘤血栓形成的显著预测指标。相比之下,D-二聚体阳性水平不是预测肿瘤血栓形成的显著指标。
HCC患者D-二聚体和TpP水平升高可能提示在肿瘤进展过程中纤维蛋白溶解和凝血持续发生。本研究表明,TpP阳性水平是HCC患者肿瘤血栓形成的预测指标,这表明TpP可能有助于识别门静脉和肝静脉中的肿瘤血栓。